BRAIN Biotech AG Financial Results Q1 2021 / 22 | Unveiling Strategic Deals & Growth Trajectory with IR

from Investor Insights from CEOs & CFOs | seat11a · host seat11a.com

BRAIN Biotech AG Elevator Pitch: Key Takeaways Q1-2022 Financials and InsightsMichael Schneiders, Investor Relations, presents an in-depth overview of BRAIN Biotech AG’s group structure, strategic deals, advanced technology, and financial highlights. Key topics include the Breatec deal, PHA 121, the SolasCure partnership, and the innovative BEC patent. Discover the company’s long-term revenue growth trajectory and their strategies for addressing Covid-19, supply chain disruptions, and inflation. Guidance and Mid-Term TargetsBRAIN Biotech AG continues to focus on innovation and development of bio-based products and solutions for nutrition, health, and the environment. Learn about their guidance and mid-term targets for sustained growth. BRAIN Group’s Diverse Collection and Global PresenceThe BRAIN Group leverages its extensive Bioarchive, consisting of microorganisms, genetic material, and natural substances. With production facilities in Germany, the UK, and the US, BRAIN integrates its biotechnological production expertise to address technological challenges and develop bio-based products used across industries. Commitment to Global Standards and Societal GoalsAs a participant in the United Nations Global Compact, BRAIN Biotech AG aligns its strategies with universal principles of human rights, labor, environment, and anti-corruption, actively contributing to societal goals. Stock Market Presence Since IPO in 2016Listed in the Prime Standard of the Frankfurt Stock Exchange since its IPO in 2016 (ISIN DE000520394), BRAIN Biotech AG remains a key player in the biotech industry. Other videos: ⁠Elevator Pitch⁠ ⁠Company Presentation⁠ ⁠Deep Dive Presentation⁠ ⁠Financial Results Presentation⁠ ⁠ESG Presentation⁠ T&C: This publication is for informational purposes only and does not constitute investment advice. By using this website, you agree to our terms and conditions outlined on ⁠www.seat11a.com/legal⁠ and ⁠www.seat11a.com/imprint⁠.

Episode metadata supplied by the publisher feed · Published Mar 1, 2022

Embed this episode

Attribution link and audio player

Ready to play

BRAIN Biotech AG Financial Results Q1 2021 / 22 | Unveiling Strategic Deals & Growth Trajectory with IR

0:00 15:57

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

The Course Mentors Podcast The Course Mentors Hey there, future course creator!Ever feel like turning your know-how into an online course is like trying to solve a Rubik's cube blindfolded? Well, grab your headphones because "The Course Mentors Podcast" is here to be your secret weapon!Meet Aimee and Odette (that's us!), your new best friends in the course creation world. We've been in the trenches for over a decade, and for the last five years, we've been rocking the online course space. Now we're here to spill all our secrets in bite-sized, 15-20 minute episodes that'll fit perfectly in your coffee breaks.No fluff, no filler - just real, actionable advice that'll take you from "um, what's a landing page?" to "holy moly, I just hit six figures!". We're talking everything from crafting your course to marketing it like a pro and building a business that'll have you pinching yourself.Whether you're dreaming of ditching the 9-to-5 grind, adding a sweet extra income str

Frequently Asked Questions

How long is this episode of Investor Insights from CEOs & CFOs | seat11a?

This episode is 15 minutes long.

When was this Investor Insights from CEOs & CFOs | seat11a episode published?

This episode was published on March 1, 2022.

Can I download this Investor Insights from CEOs & CFOs | seat11a episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!